AASLD 2017 Susanna Naggie presenting at The Liver Meeting 2017. Photo by Liz Highleyman, hivandhepatitis.comTreatment in acute infectionSofosbuvir/ledipasvir for 8 weeks cures acute HCV in people with HIV. Alina Allen presenting at The Liver Meeting 2017. Photo by Liz Highleyman, hivandhepatitis.comNAFLDWomen with fatty liver disease at higher risk for heart disease. Antoine Chaillon presenting at The Liver Meeting 2017. Photo by Liz Highleyman, hivandhepatitis.comHCV transmissionHCV infection is rising among HIV-positive gay men in San Diego. infohep news Antiviral therapy Treatment that interferes with viral assembly shows promise for hepatitis B Liz Highleyman / 18 December 2017 JNJ-56136379, an experimental drug that interferes with assembly of the hepatitis B virus (HBV) capsid, demonstrated potent antiviral activity in an early clinical trial, researchers reported at the recent 2017 AASLD Liver Meeting in ... Antiviral therapy RNA interference therapy lowers viral biomarker in people with hepatitis B Liz Highleyman / 14 December 2017 ARB-1467, a novel type of treatment for hepatitis B, reduced levels of hepatitis B surface antigen (HBsAg) when used alone, and it may play a role in combination therapy to cure the ... Antiviral therapy Immune modulator inarigivir looks promising for people with hepatitis B Liz Highleyman / 12 December 2017 Inarigivir, or SB 9200, an immune-modulating drug that has a dual mechanism of action against hepatitis B virus (HBV), reduced levels of HBV DNA, RNA and antigens, and potency was ... Antiviral therapy TAF for hepatitis B improves kidney function and bone loss Liz Highleyman / 30 November 2017 Tenofovir alafenamide (TAF) remains effective against hepatitis B virus (HBV) for 96 weeks, with no resistance detected, according to studies presented at the 2017 AASLD Liver Meeting last month in ... Antiviral therapy REP 2139 combination therapy leads to functional control of hepatitis B virus Liz Highleyman / 29 November 2017 A majority of people with chronic hepatitis B treated with a nucleic acid polymer (REP 2139 or REP 2165) plus tenofovir and pegylated interferon were able to achieve 'functional control' of hepatitis B ... Treatment in acute infection Sofosbuvir/ledipasvir for 8 weeks cures acute HCV in people with HIV Liz Highleyman / 28 November 2017 An 8-week course of sofosbuvir/ledipasvir (Harvoni) led to a sustained response in all people with HIV and genotype 1 or 4 hepatitis C virus (HCV) in the SWIFT-C study, according ... Finance, funding & health economics Model shows hepatitis C treatment is cost-effective in Japan Liz Highleyman / 27 November 2017 Treatment of chronic hepatitis C with direct-acting antivirals (DAAs) can lead to substantial savings by preventing the development of liver failure and liver cancer, according to a mathematical modelling study presented at the ... Hepatitis C elimination More work and lower drug prices are needed to eliminate hepatitis C worldwide Liz Highleyman / 27 November 2017 Eliminating hepatitis C virus (HCV) as a global public health concern is feasible, but to do this more people need to be tested and treated and prices of direct-acting antivirals ... Hepatocellular carcinoma (HCC) Nivolumab improves outcomes in liver cancer study Liz Highleyman / 13 November 2017 Nivolumab (Opdivo), a PD-1 checkpoint inhibitor that helps the immune system fight cancer, was associated with a decrease in tumour size or disease stabilisation in people with hepatocellular carcinoma (HCC) in the CheckMate ... Treatment outcomes Curing hepatitis C with DAAs linked to 71% reduction in liver cancer Liz Highleyman / 30 October 2017 People who achieved a sustained response to hepatitis C treatment lowered their risk of hepatocellular carcinoma by around 70%, regardless of whether they were treated with new direct-acting antivirals (DAAs) or older interferon-based therapy, ... View more > Editors' picks from other sources Pan-genotypic regimens New three-drug HCV regimen shows nearly 100% response in 6, 8 weeks Healio Hepatology / 30 October 2017 Hepatocellular carcinoma (HCC) HCV clearance lowers liver cancer risk by 70% no matter drug of choice Healio / 25 October 2017 Models of care Primary care pharmacists successfully manage uncomplicated HCV cases Healio / 24 October 2017 Most opioid users alter substance-use behavior after positive HCV tests Healio / 24 October 2017 Hepatocellular carcinoma (HCC) Deaths Rates of Liver Cirrhosis Exceed Those of 5 Major Cancers AASLD / 23 October 2017 Harm reduction interventions and policy Screening for Hepatitis C Improves Opioid Abuse Treatment Outcomes AASLD / 23 October 2017 View more > Other pages in this section Latest news All the news Conference news Email bulletin archive